# Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction

> **NCT01491074** · PHASE2 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 120 (actual)

## Conditions studied

- Non-ST Elevation Myocardial Infarction

## Interventions

- **DRUG:** Tocilizumab 280 mg
- **DRUG:** NaCl 0.9% 100 ml

## Key facts

- **NCT ID:** NCT01491074
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-11
- **Final completion:** 2014-04
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2014-05-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01491074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01491074, "Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01491074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*